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Key message 
Sequential administration of trastuzumab and chemotherapy compared to upfront combination 
therapy, delays chemotherapy and seems not to affect patients’ outcomes, in particular in indolent, 
non-visceral disease. The SAKK 22-99 results reinforce the accumulating evidence of treatment 
© The Author 2016. Published by Oxford University Press on behalf of the European Society for Medical 
Oncology. All rights reserved. For permissions, please email: journals.permissions@oup.com. 
de-escalation. The approach is being evaluated with dual HER2-directed therapy (SAKK 22/10 
PERNETTA trial).  
  
Abstract 
Background  
HER2-targeted therapy plus chemotherapy is standard treatment in advanced HER2+ 
breast cancer. Trastuzumab alone followed by addition of chemotherapy at disease 
progression versus upfront combination therapy has not been elucidated.  
Patients and methods 
One-hundred-seventy-five patients with measurable/evaluable HER2+ advanced disease 
without previous HER2-directed therapy were randomized to trastuzumab alone followed, 
at disease progression, by the combination with chemotherapy (Arm A) or upfront 
trastuzumab plus chemotherapy (Arm B). Chemotherapy could be stopped after ≥6 cycles 
in responding patients, trastuzumab was continued until progression. The primary endpoint 
of this superiority trial was time to progression (TTP) on combined trastuzumab-
chemotherapy (Combination-TTP) in both arms. Secondary endpoints included response 
rate, TTP, overall survival, quality of life and toxicity. 
Results 
Combination-TTP was longer than expected in both arms, 12.2 months in Arm A and 10.3 
months in Arm B and not significantly different (hazard ratio [HR] 0.7; 95% CI 0.5–1.1; P 
=0.1). Overall survival was also not significantly different (HR 0.9; 95% CI 0.6–1.5; 
P=0.55). In Arm A, the median TTP before introduction of chemotherapy was 3.7 months 
(95% CI 2.3–5.4), yet at two years 6% of patients were still on trastuzumab alone. Patients 
without visceral disease had a Combination-TTP of 21.8 months in arm A, compared with 
10.1 months in arm B (unplanned analysis HR 2.1, 95% CI 1.1–4.2, p=0.03). Patients with 
visceral disease showed no difference. Toxicity was chemotherapy-related.  
Conclusion 
The outcome of patients receiving sequential trastuzumab-chemotherapy or upfront 
combination was similar. We failed to demonstrate superiority of the sequential approach. 
These results nevertheless suggest chemotherapy and its toxicity can be deferred, 
especially in patients with indolent, non-visceral disease. Despite a larger non-inferiority 
confirmatory study would be needed, these findings represent an additional proof of 
concept that de-escalation strategies can be discussed in individual patients. 
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Introduction 
Fifteen-twenty-percent of breast cancers (BC) overexpress HER2. In advanced BC (ABC), 
HER2-targeted therapies significantly improved disease outcomes (1,2). Trastuzumab (T) 
plus pertuzumab and chemotherapy is recommended as 1st-line treatment, T-DM1 as the 
preferred 2nd/3rd-line therapy (3) as both improved overall survival (OS) (4,5).  
The impact of HER2-targeted therapy alone followed by the addition of chemotherapy at 
disease progression (PD) versus upfront combination therapy is not yet elucidated. 
In 1999, the Swiss Group for Clinical Cancer Research (SAKK) and the European Institute 
of Oncology in Milan launched a randomized phase III trial of sequential versus 
combination therapy in patients with HER2-positive ABC. The trial aimed to test the 
superiority of a sequential approach, to postpone the toxicity of chemotherapy.  
Patients and methods  
Patient selection 
Eligibility criteria: women aged 18–70 with histologically proven HER2-positive ABC. The 
original design included 1st-line, chemotherapy-naïve patients. In July 2000, based on T 
activity in chemotherapy-pretreated patients (6), amended criteria allowed 2nd/3rd-line 
chemotherapy, without previous HER2-directed therapy for ABC. First-line patients could 
have received neo/adjuvant chemotherapy completed ≥6 months before enrolment. In 
case of previous anthracyclines the cumulative dose had to be ≤240 mg/m2 doxorubicin or 
≤360 mg/m2 epirubicin. No previous taxanes were allowed. Adjuvant/palliative endocrine 
therapy (ET) was allowed. Patients must had: Eastern Cooperative Oncology Group 
(ECOG) performance status (PS) ≤1, life expectancy ≥12 weeks, adequate hematological, 
renal and liver function (total bilirubin <upper normal limits, ASAT and/or ALAT ≤3x upper 
normal limit if liver metastases), left ventricular ejection fraction (LVEF) at rest by 
echocardiography within local normal limits, clinically/radiologic measurable/evaluable 
disease (bi- or uni-dimensionally). Exclusion criteria: known brain/meningeal involvement, 
contraindications to corticosteroids, other concomitant anticancer drugs, any other serious 
disease. Bisphosphonates, started >3 months prior to enrolment, were allowed provided 
bone metastases were not the only disease indicator. 
Patients provided written informed consent and the protocol was approved by local ethics 
committees. The trial (NCT00004935) was conducted according to Good Clinical Practice, 
the Declaration of Helsinki and applicable regulatory requirements. 
Study design 
This was a multicenter, prospective, non-blinded, randomized phase III trial: patients were 
randomly assigned (1:1) to T alone followed, at PD, by the combination with chemotherapy 
(Arm A) versus the upfront combination of T and chemotherapy (Arm B) (Supplementary 
Figure 1). Randomization was stratified by degree of HER2 overexpression (3+/2+), 
estrogen receptor (ER) status, 1st- versus 2nd/3rd-line therapy, previous anthracyclines and 
institution. 
The T loading dose of 4 mg/kg/iv was followed by 2 mg/kg/iv weekly. In the 1st-line 
population (n=84) chemotherapy was weekly paclitaxel (90 mg/m2/iv-3/4 weeks). After the 
amendment chemotherapy was at investigator’s choice (taxanes, vinorelbine, cisplatin) 
according to label indications/schedules and could be stopped after ≥24 weeks (6–8 
cycles) in responding patients or after unacceptable toxicity. Reintroduction of the same 
chemotherapy under maintenance T was allowed if clinically indicated. In case of 
chemotherapy-related adverse events, chemotherapy could be changed. T was continued 
until progression. Treatment after PD under combined therapy was at investigators’ 
decision. 
Assessments 
HER2 expression was measured by immunohistochemistry (DAKO HercepTest™), 
overexpression defined according to the manufacturer’s manual. Local HER2 assessment 
was accepted for randomization with central confirmatory review. 
Patients underwent blood testing, medical history, physical examination, cardiac (ECG and 
echocardiography) and tumor (chest X-ray, bone scan, liver ultrasound) assessments ≤4 
weeks before randomization. During study treatment, blood tests were repeated on day1 
of every cycle and until recovery after the last cycle. Tumor assessment was planned after 
cycles 2-4-6 and then every 3 cycles, at PD and after the last cycle. Cardiac evaluation 
was repeated every 3 cycles during study treatment and every 3 months until recovery in 
case of LVEF decrease. 
Adverse events were graded using the NCIC-CTG Expanded Common Toxicity criteria V2. 
Specific dose reductions, delay and discontinuation algorithms were foreseen for T and 
chemotherapy. Eligible patients receiving at least one dose of T ± Chemotherapy were 
considered evaluable. 
Quality of life (QoL) evaluation was completed prior to randomization, at day1 of each 
cycle for the first six months and every second cycle from months 7-12. The assessment 
included global indicators for physical well-being, mood, functional performance, treatment 
burden and coping effort (7,8) and specific indicators for tiredness, appetite, 
nausea/vomiting, taste changes, peripheral numbness/paresthesia, pain, hair loss, and 
weight gain, based on QLQ-8 (9). Physical well-being, mood and coping effort were 
primary endpoints, based on previous data (10). All indicators were in the linear analogue 
self-assessment (LASA) format. 
Statistical analysis 
The primary endpoint was TTP on combined treatment (Combination-TTP), defined as 
interval from randomization to PD under T plus Chemotherapy. Based on the available 
evidence of a 3-month improvement in disease progression with the combination of T and 
chemotherapy (11), 153–205 events or 166–252 patients were required to detect a 
clinically meaningful 3 months increase from the 5–6 months expected median 
Combination-TTP in Arm B to 8–9 months by a log-rank test at a power of 80% and 
significance level of 5%, with a group-sequential design allowing for two interim analyses. 
Secondary endpoints were response rate, time to 1st TTP and to treatment failure 
(Combination-TTP plus toxicity events and refusal; TTF), OS, toxicity, and QoL.  
Analyses were done according to the intention-to-treat principle. Survival curves were 
determined using Kaplan-Meier methods and compared using the log-rank test. 
Frequencies were compared using Fisher’s exact tests. HRs with 95% CI were computed 
with uni/multivariable proportional hazard models. QoL scores were plotted over time and 
by treatment. Testing was restricted to values from baseline and cycle 1 in a mixed effects 
model. In both Cox and mixed models interactions were assessed by Wald-type tests. P-
values are two-sided, not adjusted for multiple testing, and considered significant if <0.05. 
Analyses were carried out using SAS v9.2 or the R software package (www.r-project.org) 
version 3.2 or later. 
Results 
Patient characteristics  
From September 1999–January 2013, 175 patients were randomized in 9 centers to 
sequential (Arm A n=86) or combination (Arm B n=87) treatment: 2 patients were not 
eligible (1 HER2-negative centrally, 1 treatment refusal; CONSORT diagram). The interim 
analyses in October 2004-July 2011 did not cross the predefined boundaries for either 
futility or efficacy. 
Baseline characteristics were well balanced (Table 1). Median age was 55 years (33–79), 
99% of patients had an ECOG PS of 0-1. One-hundred-twenty-five patients (72%) 
received study treatment as 1st-line, 48 patients (28%), without previous T, as 2nd/3rd-line 
(112 taxanes, 49 vinorelbine, 2 both, 10 in arm A never started chemotherapy); 77 patients 
(45%) had neo/adjuvant chemotherapy (40% anthracycline-based), 102 patients (59%) 
radiation therapy (24% for ABC). Sixty-three-percent of patients (109) had ER+ and/or 
progesterone-receptor-positive (PR+) tumors: 67% (73) had received ET as adjuvant (48, 
68%) or palliative (23, 32%) treatment (2 unknown indications). One-hundred-fourteen 
patients (66%) had visceral disease, 39% of them (44) both visceral and bone disease, 
17% (19) had bone disease only, 72% of the patients (124) had ≥3 disease sites. One third 
of patients had ABC at diagnosis.  
Treatment  
At cutoff date (November 2014) 3 patients were still under T alone, 1 under maintenance T 
after chemotherapy interruption. The median TTF was 11.5 months (95% CI 8.9–18.1) in 
Arm A and 6.4 months (95% CI 5.6–7.0) in Arm B. Fifty-two patients (30%) were censored 
(45 off-protocol treatment before PD, 7 maintenance metronomic chemotherapy/ET before 
PD). Seven patients were lost to follow-up, 4 experiencing an event and 2 starting a new 
treatment. The overall exposure to chemotherapy in months was similar in both arms.  
Efficacy 
At 77.7 months median follow-up, 53 and 68 events occurred in Arm A and B, respectively. 
The median Combination-TTP was 12.2 months in Arm A (95% CI 9.2-15.3) and 10.3 
months in Arm B (95% CI 9.2–12.6) (HR 0.7, 95% CI 0.5–1.1; p=0.1) (Figure 1A). In Arm A 
the median TTP before introduction of chemotherapy was 3.7 months (HR 2.1; p<0.001) 
(Figure 1B): early PD (<2 months) occurred in 24 patients in Arm A (28%) and 4 patients in 
Arm B (4%). Twelve-percent of patients in Arm A received T alone for one year, 6% for two 
years. 
Death occurred in 65 patients in Arm A and 68 patients in Arm B. The median OS was 
35.6 months in Arm A (95% CI 30.9–41.4) and 36.3 months in Arm B (95% CI 30.6-40.5), 
(HR 0.9; p=0.55) (Figure 1C).  
In an unplanned subgroup analysis, Combination-TTP in Arm A was 21.8 months (95% CI 
11.3–NA) in patients without visceral disease and 10.4 months (95% CI 8.3–12.2) in 
patients with visceral disease. In Arm B, Combination-TTP was similar (10.1 months, 95% 
CI 8.5–17.3 and 10.3 months, 95% CI 8.7–12.3) in patients with or without visceral disease 
(pinteraction=0.055; Figure 2A). For TTP, the interaction between arm and visceral disease 
was significant (Pinteraction=0.03; Figure 2B). For OS, no evidence for an interaction between 
treatment and visceral disease status was found (Pinteraction=1; Figure 2C).  
Combination-TTP was significantly shorter in ER+/PR+ patients who received previous 
palliative ET (10.0 months, 95% CI 8.8–12.7) than in ET-naïve patients (18.1 months, 95% 
CI 11.0–21.8) (logrank p=0.03). Of note, only 2 of these patients had a disease response 
under palliative ET. Small numbers prevented a stratified efficacy analysis of HER2 
2+/3+patients. Brain metastases were reported in 6% (7/115) of progressing patients (1 in 
Arm A, 6 in Arm B).  
No interaction was evident between Combination-TTP and age (Supplementary Figure 2). 
The chemotherapy backbone (vinorelbine versus taxanes) did not impact TTP (HR 1.0, 
95% CI 0.5–1.9, p=0.89). 
Quality of life and safety 
After 3-4 weeks’ therapy (first on-treatment visit) patients in both arms reported better 
mood and less coping effort (all p <0.001) compared to baseline. Patients receiving 
combined treatment upfront reported substantially more hair loss (pinteraction<0.0001) and 
weight gain (p<0.01). A descriptive investigation (Supplementary Figure 3) indicates these 
differences persist over the first six cycles, as associated with more treatment burden. The 
remaining global QoL indicators showed no substantial differences between arms. 
Toxicity was chemotherapy- and regimen-related and not substantially different in the 2 
arms: grade 3-4 toxicity was very rare (Table 2). Cardiac toxicity was mild (no grade 4, 1 
G3 cardiac failure in arm A). No treatment-related death was reported. 
Discussion 
The sequential administration of trastuzumab followed at PD by the addition of 
chemotherapy delays chemotherapy and its toxicity.  
Our trial, designed as a superiority trial, failed to show a benefit in Combination-TTP in the 
sequential arm but we observed a longer than projected Combination-TTP, not 
significantly different in the 2 arms. Survival was also not significantly different between 
arms, despite a higher early progression rate in the sequential arm. When looking at 
patients without visceral disease, in an unplanned subgroup analysis, trastuzumab alone 
allowed a remarkably long disease control (up to 1-2 years) resulting in a significantly 
longer Combination-TTP compared to upfront combination therapy. These hypothesis 
generating results seem to suggest chemotherapy can be safely postponed in the 
subgroup of patients without visceral disease.  
Two trials addressed timing of chemotherapy in presence of trastuzumab. In the Japanese 
JO17360 1st-line phase III trial, 112 patients were randomized to T followed at PD by T 
plus docetaxel (D) or combination T+D (12). Accrual was prematurely stopped because 
progression-free survival (PFS) was significantly worse in the sequential arm (3.7 versus 
14.6 months, p<.01). OS was also significantly longer in the T+D arm (HR 2.72; p=0.04), 
although it was not possible to calculate the median OS because the number of deaths 
was very low in both arms.  
In the Dutch Breast Cancer Trialists’ Group 1st-line phase II HERTAX Trial, 101 patients 
were randomized between upfront T+D and sequential T followed at PD by D alone (13). 
The primary endpoint was PFS after completed sequential/combination therapy. 
Sequential and combination treatments resulted in similar PFS (9.9 versus 9.4 months). 
The trial was not powered for OS analysis but the overall response rate (ORR) was 
significantly lower in the sequential arm (79% versus 53%, p=0.016).  
Several aspects distinguish the three trials. Although the Japanese study had the same 
design as ours, in the sequential arm PFS was calculated at PD with single agent T and 
not after the addition of chemotherapy: our trial evaluated TTP under combination therapy 
in both arms as we did want to study timing of chemotherapy, not if we can omit it. The 
Dutch trial explored sequential T followed at PD by single-agent chemotherapy. Our trial 
was the only to evaluate the impact of combination therapy in both arms while maintaining 
T at PD. 
In our trial, patients under sequential treatment reported more side effects but no 
substantial difference in physical well-being, mood or coping effort: however, the sample 
size was too small for a conclusive QoL evaluation. 
Our trial has several limitations. The planned accrual in 5 years (40–50 patients/year) was 
not achieved and >13 years were required to enroll 175 patients. Different reasons explain 
this delay: the availability of T with chemotherapy other than paclitaxel outside the trial and 
the need to continue chemotherapy until PD, both removed by the amendment; emerging 
new anti-HER2 therapies over time. A substantial number of patients were censored due 
to off-protocol treatments, mainly maintenance ET/metronomic chemotherapy added to 
trastuzumab. However, even when considering them as events the results did not change 
substantially. Failure to enroll an appropriate number of participants and to stick to protocol 
therapy resulted in reduction of the number of events and statistical power, prolonging 
study duration and decreasing the possibility to show a significant difference between the 
two tested strategies. 
Despite these limitations, we found no significant differences in TTP and OS when 
postponing chemotherapy in patients under HER2-directed therapy. This result, not 
foreseen in the trial design in 1999, is hypothesis-generating and of clinical interest 
especially in patients without visceral disease, recognizing the barriers to conduct a new 
trial in this setting and despite derived from an unplanned subgroup analysis. QoL, safety 
and cost considerations should also be part of the individual decision-making algorithm.  
Our results represent an additional proof of concept of the expanding de-escalating 
strategy in HER2-positive BC, shown to be promising in early disease (14) and in the 
neoadjuvant setting (15). In ABC sequential single-agent chemotherapy is already the 
standard of care, with combination chemotherapy reserved for rapidly progressive or 
highly symptomatic disease (3). 
HER2-targeted therapies and strategies are under continuous development: despite major 
improvements over the last 15 years, optimisation of sequencing, combination and 
alternating strategies is still needed to further impact outcomes. The SAKK 22/10 trial 
(PERNETTA trial NCT01835236), evaluating in 1st-line patients the sequential dual anti-
HER2 targeting (Trastuzumab/Pertuzumab) strategy, finished accrual and will hopefully 
add evidence to better plan treatment individualization. 
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Table 2. Treatment-related selected adverse events occurring in ≥10% of patients 
 
 
Figure 1: TTP-TChemo (A), TTP (B), OS (C) according to treatment arm. 
TTP: time to progression. TTP-TChemo: TTP on combined trastuzumab-chemotherapy. OS: 
overall survival. 
Figure 2: TTP-TChemo (A), TTP (B), OS (C) according to treatment arm and presence of visceral 
disease (VD) 
 
Supplementary Figure 1: Study design 
Supplementary Figure 2: TTP-TChemo according to age and treatment arm 
Supplementary Figure 3: Quality of Life 
 
Table 1. Patients’ characteristics  
 
 
 
 
  
 
 arm A 
(n=86) 
arm B 
(n=87) 
Age (years)  
Median (range) 53 (33-79) 57 (33-79) 
ECOG PS (%)   
0-1 85 (99%) 87 (100%) 
N° CT regimens (%)  
1
st
 line 63 (73%) 62 (71%) 
2
nd
-3
rd
 line 23 (27%) 25 (29%) 
ER status (%)  
Positive 51 (59%) 52 (60%) 
Negative 35 (41%) 35 (40%) 
Adjuvant 
Anthracyclines (%) 
 
HER2 2+ 11 (13%) 13 (15%) 
No 52 (60%) 53 (61%) 
Yes  34 (40%) 34 (39%) 
Endocrine therapy (%)   
No 16 (33%) 17 (32%) 
Adjuvant 22 (45%) 25 (47%) 
Palliative 11 (22%) 11 (21%) 
Disease sites (%)  
Bone only 7 (8%) 12 (14%) 
Visceral only 32 (37%) 38 (44%) 
Visceral + bone  26 (30%) 18 (21%) 
Advanced disease at 
diagnosis (%) 
25 (29%) 29 (33%) 
Table 2. Treatment-related selected adverse events occurring in ≥10% of patients 
 
 All grades Grade 3-4 
arm A  
(T→TChemo) 
(n=86) 
arm B 
(TChemo) 
(n=88) 
arm A  
(T→TChemo)  
(n=86) 
arm B  
(TChemo) 
(n=88) 
Neutropenia 46 (53%) 63 (71%) 13 (15%) 24 (27%) 
Sensory 
neuropathy 
43 (50%) 48 (54%) 6 (6%) 6 (7%) 
Arthralgia/Myalgia 49 (57%) 41 (46%) 1 (1%) 1 (1%) 
Lethargy 38 (44%) 41 (46%) 1 (1%) 1 (1%) 
Alopecia  34 (39%) 44 (50%) 9 (10%) 9 (10%) 
Nausea 30 (35%) 26 (29%) 1 (1%) 0 
Diarrhoea  26 (30%) 22 (25%) 1 (1%) 2 (2%) 
Infection without 
neutropenia 
23 (27%) 19 (21%) 4 (4%) 4 (4%) 
Constipation 16 (19%) 23 (26%) 1 (1%) 0 
Fever without 
infection 
23 (27%) 11 (13%) 0 0 
Loss of appetite 18 (21%) 10 (11%) 1 (1%) 0 
Vomiting 16 (19%) 8 (9%) 0 0 
Peripheral 
oedema  
11 (13%) 13 (14%) 0 0 
 
 
Figure Legends  
CONSORT 2010 Flow Diagram 
Figure 1: TTP-TChemo (A), TTP (B), OS (C) according to treatment arm. 
TTP: time to progression. TTP-TChemo: TTP on combined trastuzumab-chemotherapy. OS: 
overall survival. 
Figure 2: TTP-TChemo (A), TTP (B), OS (C) according to treatment arm and presence of visceral 
disease (VD) 
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 Figure 1A. TTP-TChemo according to treatment arm 
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Figure 1B. TTP according to treatment arm 
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Figure 1C. OS according to treatment arm 
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Figure 2A. TTP-TChemo according to treatment arm and visceral disease status 
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Figure 2B. TTP according to treatment arm and visceral disease status  
 
  
time (years)
P
ro
b
a
b
il
it
y
 o
f 
T
T
P
/
/
/
/
/
/
/ //
/
/
/
/ /
/
//
/
/
/ /
0 1 2 3 4 5 6
0
0.2
0.4
0.6
0.8
1
# at risk
no VD: A
no VD: B
VD: A
VD: B
28 7 4 3 1 1 1
31 10 4 2 2 1 0
57 3 1 1 1 1 1
56 19 4 3 2 1 1
no visceral disease: Arm A
no visceral disease: Arm B
visceral disease: Arm A
visceral disease: Arm B
Figure 2C. OS according to treatment arm and visceral disease status  
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Supplementary Figure 2: TTP-TChemo according to age and treatment arm 
 
 
  
time (years)
P
ro
b
a
b
il
it
y
 o
f 
T
T
P
-T
C
h
e
m
o //
/
/
/
//
/
/
/
/
/ //
//
/
/
/
/
/
/ /
/
/
/
/
/
//
/
/
/
/ /
/
/
/
/
///
/
/
/
/
0 1 2 3 4 5 6
0
0.2
0.4
0.6
0.8
1
# at risk
A: >60y
A: 40–60y
A: <40y
B: >60y
B: 40–60y
B: <40y
27 11 4 3 2 2 2
50 16 4 1 0 0 0
9 2 1 1 0 0 0
34 15 4 2 2 1 0
46 12 3 2 1 1 1
7 2 1 1 1 0 0
Arm A: elderly
Arm A: middle
Arm A: young
Arm B: elderly
Arm B: middle
Arm B: young
Supplementary Figure 3. Quality of Life 
 
 
